Ironwood Pharmaceuticals, Inc. (IRWD)
-NasdaqGS 12.83 
0.31(2.48%) May 24, 4:00PM EDT|After Hours
:
12.52 0.31 (2.42%) May 24, 5:00PM EDT
| Prev Close: | 12.52 |
|---|
| Open: | 12.57 |
|---|
| Bid: | 12.50 x 500 |
|---|
| Ask: | 13.00 x 300 |
|---|
| 1y Target Est: | 16.13 |
|---|
| Beta: | 1.68 |
|---|
| Next Earnings Date: | 17-Jul-13 |
|---|
| Day's Range: | 12.50 - 12.93 |
|---|
| 52wk Range: | 10.01 - 19.67 |
|---|
| Volume: | 986,513 |
|---|
| Avg Vol (3m): | 1,093,210 |
|---|
| Market Cap: | 1.39B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.22 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat 10:10AM EDT)
- Positive Data from Synergy PharmaZacks(Fri, May 24)
- IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, May 24)
- Ironwood Pharma Prices Stock OfferingZacks(Thu, May 23)
- Grab IRWD Even Cheaper Than Its Secondary?at Forbes(Thu, May 23)
- Ironwood Pharmaceuticals Is Now Oversold (IRWD)at TheStreet(Wed, May 22)
- Ironwood Pharmaceuticals Prices Public Offering of Common StockBusiness Wire(Tue, May 21)
- Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatideat Seeking Alpha(Tue, May 21)
- Ironwood Pharma Plans 10.5M-Share Offeringat Seeking Alpha(Mon, May 20)
- Ironwood Pharmaceuticals Announces Proposed Public Offering of Common StockBusiness Wire(Mon, May 20)
- IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 20)
- Ironwood Linzess may not be suitable for some patients, says Cantorat theflyonthewall.com(Mon, May 20)
- Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013Business Wire(Tue, May 14)
- Top Life Science Investors Of 2013at Forbes(Thu, May 9)
- Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Health Care ConferenceBusiness Wire(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 9.58 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.79 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.69 |
|---|
| Mean Recommendation*: | 2.9 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The companys lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable...
View More